{"id":199315,"date":"2026-08-12T13:48:40","date_gmt":"2026-08-12T08:18:40","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=199315"},"modified":"2026-08-12T13:48:42","modified_gmt":"2026-08-12T08:18:42","slug":"generic-pharmas-q1-results-fy27-pat-loss-0-17-crore","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/generic-pharmas-q1-results-fy27-pat-loss-0-17-crore\/","title":{"rendered":"Generic Pharmas Q1 FY27 Results: Revenue Rs 49 Cr, Net Loss Rs 0.17 Cr and Key Highlights"},"content":{"rendered":"<div class=\"meta-block\"><\/div>\n<p style=\"border-left: 4px solid #1F4E79; background: #EBF3FB; padding: 10px 16px; font-style: italic;\"><em>Generic Pharmas Q1 FY27: Revenue Rs 49 Cr (+312.77% YoY). Net Loss Rs 0.17 Cr (-114.29% YoY). Results August 11, 2026. CMP Rs 1.03.<\/em><\/p>\n<p>Generic Pharmas Q1 FY27 results were announced on August 11, 2026, reporting a net loss of Rs 0.17 crore, compared with a net profit of Rs 1 crore in Q1 FY26. Revenue from operations grew 312.77% year on year to Rs 49 crore from Rs 12 crore in Q1 FY26. The Generic Pharmas Q1 FY27 results are on a consolidated basis for the quarter ended June 30, 2026.<\/p>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&amp;utm_medium=generic-pharmas-q1-results-fy27-pat-loss-0-17\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/generic-pharmas-q1-results-fy27-pat-loss-0-17-crore\/#Generic_Pharmas_Q1_FY27_Financial_Highlights\" title=\"Generic Pharmas Q1 FY27 Financial Highlights\">Generic Pharmas Q1 FY27 Financial Highlights<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/generic-pharmas-q1-results-fy27-pat-loss-0-17-crore\/#Generic_Pharmas_Q1_FY27_Performance_Analysis\" title=\"Generic Pharmas Q1 FY27 Performance Analysis\">Generic Pharmas Q1 FY27 Performance Analysis<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/generic-pharmas-q1-results-fy27-pat-loss-0-17-crore\/#Key_Business_Factors_in_Generic_Pharmas_Q1_FY27\" title=\"Key Business Factors in Generic Pharmas Q1 FY27\">Key Business Factors in Generic Pharmas Q1 FY27<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/generic-pharmas-q1-results-fy27-pat-loss-0-17-crore\/#1_Revenue_Context_in_Q1_FY27\" title=\"1. Revenue Context in Q1 FY27\">1. Revenue Context in Q1 FY27<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/generic-pharmas-q1-results-fy27-pat-loss-0-17-crore\/#2_Operating_Cost_Pressure_Compressed_Gross_Margins\" title=\"2. Operating Cost Pressure Compressed Gross Margins\">2. Operating Cost Pressure Compressed Gross Margins<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/generic-pharmas-q1-results-fy27-pat-loss-0-17-crore\/#3_Net_Loss_Persists_in_Q1_FY27\" title=\"3. Net Loss Persists in Q1 FY27\">3. Net Loss Persists in Q1 FY27<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/generic-pharmas-q1-results-fy27-pat-loss-0-17-crore\/#Dividend_Details\" title=\"Dividend Details\">Dividend Details<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/generic-pharmas-q1-results-fy27-pat-loss-0-17-crore\/#Generic_Pharmas_FY27_Outlook_After_Q1_Results\" title=\"Generic Pharmas FY27 Outlook After Q1 Results\">Generic Pharmas FY27 Outlook After Q1 Results<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/generic-pharmas-q1-results-fy27-pat-loss-0-17-crore\/#Generic_Pharmas_Stock_Performance\" title=\"Generic Pharmas Stock Performance\">Generic Pharmas Stock Performance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/generic-pharmas-q1-results-fy27-pat-loss-0-17-crore\/#Key_Risks_to_Watch_After_Generic_Pharmas_Q1_FY27_Results\" title=\"Key Risks to Watch After Generic Pharmas Q1 FY27 Results\">Key Risks to Watch After Generic Pharmas Q1 FY27 Results<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/generic-pharmas-q1-results-fy27-pat-loss-0-17-crore\/#1_Sector-Specific_Demand_Headwinds\" title=\"1. Sector-Specific Demand Headwinds\">1. Sector-Specific Demand Headwinds<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/generic-pharmas-q1-results-fy27-pat-loss-0-17-crore\/#2_Input_Cost_and_Margin_Pressure\" title=\"2. Input Cost and Margin Pressure\">2. Input Cost and Margin Pressure<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/generic-pharmas-q1-results-fy27-pat-loss-0-17-crore\/#3_Macroeconomic_and_Regulatory_Uncertainty\" title=\"3. Macroeconomic and Regulatory Uncertainty\">3. Macroeconomic and Regulatory Uncertainty<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/generic-pharmas-q1-results-fy27-pat-loss-0-17-crore\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/generic-pharmas-q1-results-fy27-pat-loss-0-17-crore\/#Frequently_Asked_Questions_on_Generic_Pharmas_Q1_FY27_Results\" title=\"Frequently Asked Questions on Generic Pharmas Q1 FY27 Results\">Frequently Asked Questions on Generic Pharmas Q1 FY27 Results<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/generic-pharmas-q1-results-fy27-pat-loss-0-17-crore\/#When_were_the_Generic_Pharmas_Q1_FY27_results_announced\" title=\"When were the Generic Pharmas Q1 FY27 results announced?\">When were the Generic Pharmas Q1 FY27 results announced?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/generic-pharmas-q1-results-fy27-pat-loss-0-17-crore\/#What_is_the_PAT_in_the_Generic_Pharmas_Q1_FY27_results\" title=\"What is the PAT in the Generic Pharmas Q1 FY27 results?\">What is the PAT in the Generic Pharmas Q1 FY27 results?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/generic-pharmas-q1-results-fy27-pat-loss-0-17-crore\/#What_was_the_revenue_in_the_Generic_Pharmas_Q1_FY27_results\" title=\"What was the revenue in the Generic Pharmas Q1 FY27 results?\">What was the revenue in the Generic Pharmas Q1 FY27 results?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/generic-pharmas-q1-results-fy27-pat-loss-0-17-crore\/#Did_Generic_Pharmas_announce_any_dividend_with_the_Q1_FY27_results\" title=\"Did Generic Pharmas announce any dividend with the Q1 FY27 results?\">Did Generic Pharmas announce any dividend with the Q1 FY27 results?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/generic-pharmas-q1-results-fy27-pat-loss-0-17-crore\/#What_is_the_Generic_Pharmas_FY27_outlook_after_Q1_results\" title=\"What is the Generic Pharmas FY27 outlook after Q1 results?\">What is the Generic Pharmas FY27 outlook after Q1 results?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/univest.in\/blogs-2\/generic-pharmas-q1-results-fy27-pat-loss-0-17-crore\/#Is_Generic_Pharmas_a_good_buy_after_Q1_FY27_results\" title=\"Is Generic Pharmas a good buy after Q1 FY27 results?\">Is Generic Pharmas a good buy after Q1 FY27 results?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Generic_Pharmas_Q1_FY27_Financial_Highlights\"><\/span><strong>Generic Pharmas Q1 FY27 Financial Highlights<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The table below presents key financial metrics from the Generic Pharmas Q1 FY27 results against the corresponding quarter of the prior year.<\/p>\n<table>\n<thead>\n<tr>\n<th>Metric<\/th>\n<th>Q1 FY27 (Jun 2026)<\/th>\n<th>Q1 FY26 (Jun 2025)<\/th>\n<th>YoY Change<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Revenue from Operations (Rs Cr)<\/td>\n<td>Rs 49 Cr<\/td>\n<td>Rs 12 Cr<\/td>\n<td>+312.77%<\/td>\n<\/tr>\n<tr>\n<td>Gross Profit (Rs Cr)<\/td>\n<td>Rs 0.28 Cr<\/td>\n<td>Rs 0.67 Cr<\/td>\n<td>-57.88%<\/td>\n<\/tr>\n<tr>\n<td>Net Profit \/ (Loss) &#8211; PAT (Rs Cr)<\/td>\n<td>Rs -0.17 Cr<\/td>\n<td>Rs 1 Cr<\/td>\n<td>-114.29%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<div style=\"background: #E8EAFF; border-radius: 14px; padding: 28px 32px 24px; margin: 24px 0; font-family: -apple-system,BlinkMacSystemFont,'Segoe UI',Roboto,sans-serif; cursor: pointer; max-width: 100%; box-sizing: border-box;\">\n<p style=\"font-size: 20px; font-weight: bold; color: #0a0a23; margin: 0 0 12px 0; line-height: 1.3;\">3 Stocks Building Serious Momentum Right Now<\/p>\n<p style=\"font-size: 15px; color: #3a3a5c; margin: 0 0 14px 0; line-height: 1.6;\">When <strong style=\"color: #0a0a23;\">Univest analysts<\/strong> identify high-conviction stock opportunities, <em>investors pay attention.<\/em><\/p>\n<p style=\"font-size: 15px; color: #3a3a5c; margin: 0 0 14px 0; line-height: 1.6;\">Our research team has shortlisted the <strong style=\"color: #0a0a23;\">Top Stocks to Buy<\/strong> based on current market momentum, sector trends and growth potential for 2026.<\/p>\n<ul style=\"margin: 0 0 16px 20px; padding: 0; color: #3a3a5c; font-size: 15px; line-height: 1.8;\">\n<li>Discover stocks investors are actively accumulating<\/li>\n<li>High-conviction opportunities backed by research<\/li>\n<li>Designed for the next phase of market growth<\/li>\n<\/ul>\n<p style=\"font-size: 15px; color: #3a3a5c; margin: 0 0 20px 0;\">Unlock the latest <a style=\"color: #3b7fff; font-weight: bold; text-decoration: none;\" href=\"https:\/\/univest.in\/user\/log-in?redirectUrl=%2Fuser%2Fpayment%3FplanType%3DALL_PRO%2BPLANS%26cacheClear%3D1780639629052\">Top Stock Picks<\/a> on Univest<\/p>\n<p><a style=\"display: inline-block; background: #3B7FFF; color: #fff; font-size: 15px; font-weight: 600; padding: 13px 28px; border-radius: 50px; letter-spacing: 0.2px; text-decoration: none;\" href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&amp;utm_medium=generic-pharmas-q1-fy27\" target=\"_blank\" rel=\"noopener\">See the Stocks \u2192<\/a><\/p>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"Generic_Pharmas_Q1_FY27_Performance_Analysis\"><\/span><strong>Generic Pharmas Q1 FY27 Performance Analysis<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/screeners\"><strong>Use the Univest Screener to Track Live Fundamentals of Indian Stocks<\/strong><\/a><\/p>\n<p>The Generic Pharmas Q1 FY27 results show revenue growth of 312.77% year on year to Rs 49 crore. Gross profit stood at Rs 0.28 crore against Rs 0.67 crore in Q1 FY26.<\/p>\n<p>Net loss in the June 2026 quarter was Rs 0.17 crore, swinging from a profit of Rs 1 crore in Q1 FY26. Investors should verify these figures against official BSE and NSE filings.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Business_Factors_in_Generic_Pharmas_Q1_FY27\"><\/span><strong>Key Business Factors in Generic Pharmas Q1 FY27<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"1_Revenue_Context_in_Q1_FY27\"><\/span><strong>1. Revenue Context in Q1 FY27<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Revenue grew 312.77% year on year to Rs 49 crore. Despite this trend, the company&#8217;s Pharmaceuticals operations remain under pressure on the profitability front.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"2_Operating_Cost_Pressure_Compressed_Gross_Margins\"><\/span><strong>2. Operating Cost Pressure Compressed Gross Margins<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Gross profit in the June 2026 quarter stood at Rs 0.28 crore, indicating partial operational cost recovery despite the net loss.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"3_Net_Loss_Persists_in_Q1_FY27\"><\/span><strong>3. Net Loss Persists in Q1 FY27<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The company reported a net loss of Rs 0.17 crore, compared with a net profit of Rs 1 crore in Q1 FY26. A return to profitability will require either revenue scaling or significant cost rationalisation.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Dividend_Details\"><\/span><strong>Dividend Details<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>No dividend has been declared alongside the Generic Pharmas Q1 FY27 results for the quarter ended June 2026. Investors may track any future dividend announcements on BSE and NSE.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Generic_Pharmas_FY27_Outlook_After_Q1_Results\"><\/span><strong>Generic Pharmas FY27 Outlook After Q1 Results<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The June 2026 quarterly results for Generic Pharmas present a mixed picture heading into FY27. Revenue recovery and cost rationalisation will be critical to strengthening the financial position. Investors tracking Generic Pharmas Q1 results should monitor management guidance, sector conditions in Pharmaceuticals, and any strategic developments through the year.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Generic_Pharmas_Stock_Performance\"><\/span><strong>Generic Pharmas Stock Performance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p style=\"margin-top: 24px;\"><em>Download the <a href=\"https:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"https:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Generic Pharmas live share price and upcoming quarterly results.<\/em><\/p>\n<p>Generic Pharmas share price stood at Rs 1.03 on August 11, 2026, the day the quarterly results were declared. Post-results, the market will assess whether the Pharmaceuticals company&#8217;s financial performance justifies the current valuation. Investors should verify the latest price and fundamentals on BSE and NSE before any investment decision.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_to_Watch_After_Generic_Pharmas_Q1_FY27_Results\"><\/span><strong>Key Risks to Watch After Generic Pharmas Q1 FY27 Results<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"1_Sector-Specific_Demand_Headwinds\"><\/span><strong>1. Sector-Specific Demand Headwinds<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>A slowdown in the Pharmaceuticals sector could weigh on Generic Pharmas revenue and profitability beyond what the June 2026 quarter currently indicates.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"2_Input_Cost_and_Margin_Pressure\"><\/span><strong>2. Input Cost and Margin Pressure<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Rising raw material or operational costs could compress gross margins and limit net profit improvement in subsequent quarters of FY27.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"3_Macroeconomic_and_Regulatory_Uncertainty\"><\/span><strong>3. Macroeconomic and Regulatory Uncertainty<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Inflation, interest rate movements, and regulatory shifts remain key risks to the Generic Pharmas earnings trajectory through FY27.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Generic Pharmas Q1 FY27 results report revenue of Rs 49 crore and a net loss of Rs 0.17 crore, compared with a net profit of Rs 1 crore in Q1 FY26. The June 2026 quarterly results highlight challenges in the Pharmaceuticals space. Investors should review the full financial statements on BSE and NSE and consult a SEBI-registered advisor before any investment decision.<\/p>\n<div style=\"background: #CC0000; border-radius: 8px; padding: 16px 20px; margin: 24px 0;\">\n<p style=\"color: #ffffff; font-size: 13px; line-height: 1.7; margin: 0;\"><strong style=\"color: #ffffff;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions_on_Generic_Pharmas_Q1_FY27_Results\"><\/span><strong>Frequently Asked Questions on Generic Pharmas Q1 FY27 Results<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"When_were_the_Generic_Pharmas_Q1_FY27_results_announced\"><\/span><strong>When were the Generic Pharmas Q1 FY27 results announced?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The June 2026 quarterly results for Generic Pharmas were announced on August 11, 2026, covering the quarter ended June 30, 2026. The consolidated results were filed with BSE and NSE on the same date.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_PAT_in_the_Generic_Pharmas_Q1_FY27_results\"><\/span><strong>What is the PAT in the Generic Pharmas Q1 FY27 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Net loss was Rs 0.17 crore in the June 2026 quarter, compared with a net profit of Rs 1 crore in Q1 FY26.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_was_the_revenue_in_the_Generic_Pharmas_Q1_FY27_results\"><\/span><strong>What was the revenue in the Generic Pharmas Q1 FY27 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue for the June 2026 quarter rose 312.77% year on year to Rs 49 crore from Rs 12 crore in Q1 FY26.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Did_Generic_Pharmas_announce_any_dividend_with_the_Q1_FY27_results\"><\/span><strong>Did Generic Pharmas announce any dividend with the Q1 FY27 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> No dividend has been declared alongside the June 2026 quarterly results of Generic Pharmas. Investors may track future dividend announcements on the BSE and NSE portals.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_Generic_Pharmas_FY27_outlook_after_Q1_results\"><\/span><strong>What is the Generic Pharmas FY27 outlook after Q1 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The June 2026 quarterly data signals a challenging start to FY27 for Generic Pharmas. Revenue trends, margin performance, and Pharmaceuticals sector demand will be the key factors to watch through the rest of the financial year.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Generic_Pharmas_a_good_buy_after_Q1_FY27_results\"><\/span><strong>Is Generic Pharmas a good buy after Q1 FY27 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The Q1 FY27 quarterly performance of Generic Pharmas reflects challenging trends. This article is for educational purposes only and does not constitute investment advice. Please consult a SEBI-registered investment advisor before making any investment decision.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Generic Pharmas Q1 FY27 results: Revenue Rs 49 Cr, Net Loss Rs 0.17 Cr. Key highlights, performance, FY27 outlook. Read full results analysis here.<\/p>\n","protected":false},"author":35,"featured_media":199314,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[3802],"class_list":["post-199315","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-news"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["199314"],"_edit_lock":["1786522732:29"],"_last_editor_used_jetpack":["block-editor"],"rank_math_primary_category":["842"],"rank_math_seo_score":["71"],"rank_math_title":["Generic Pharmas Q1 FY27 Results: Revenue and PAT Highlights"],"rank_math_description":["Generic Pharmas Q1 FY27 results: Revenue Rs 49 Cr, Net Loss Rs 0.17 Cr. Key highlights, performance, FY27 outlook. Read full results analysis here."],"rank_math_focus_keyword":["Generic Pharmas Q1 FY27 results"],"rank_math_robots":["a:2:{i:0;s:8:\"nofollow\";i:1;s:7:\"noindex\";}"],"_edit_last":["29"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["36445"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/08\/generic-pharmas-q1-results-fy27-pat-loss-0-17-crore.png","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/199315","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/35"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=199315"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/199315\/revisions"}],"predecessor-version":[{"id":199366,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/199315\/revisions\/199366"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/199314"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=199315"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=199315"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=199315"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}